A platform for discovering novel drug combinations through smarter data analysis

A platform for discovering novel drug combinations through smarter data analysis

Title A platform for discovering novel drug combinations through smarter data analysis

Summary
A European start-up has developed a proprietary biomedical data platform for better patient outcomes & acceleration of the development of novel treatment strategies for rare disease patients. The platform is designed to do this in a fraction of the time/cost of traditional drug development approaches. The platform focuses on clinical responder analyses, drug combinations & indication extensions. The company offers joint venture agreements, license agreements or research cooperation agreements.

Description
As many as 7000 rare diseases are affecting 300 million patients worldwide; 40 million in the EU and 30 million in the US. The current approaches are ineffective, costly and time-consuming.

A European start-up´s innovative network pharmacology platform has the potential to radically change how drugs are combined for better patient outcomes and to accelerate the development of novel treatment strategies for rare disease patients with an unmet medical need, at a fraction of the time and cost of traditional drug discovery approaches.

The technology can unlock hidden insights on mechanisms, safety and efficacy from unstructured data.

The platform combines natural language processing (NLP), machine learning (ML) and network analysis algorithms with public/private medical records, clinical trials and biomedical journal insights. It integrates patient biopsy data to identify novel drug combinations based on safety and efficacy.

The system has been tested in real-world clinical-stage projects with known big pharma companies.

Now the request is to further develop the system into one secure, federated platform that can be integrated into pharmaceutical and health systems workflow and to be applied to rare disease drug combinations programs in partnership with patient groups, pharma companies and academic teams.

Hence they would like to partner with Pharma/Biotech companies and clinicians on specific diseases, starting with rare cancers like Multiple Myeloma.

The type of co-operation and taks of the partner sought is:
– Joint Venture Agreement: joint collaboration on R&D development
– Research cooperation agreement: further development
– License agreement: the company offers the platform to licensees

Advantages and Innovations
– The European company´s biomedical data platform and product tool suite differentiate from competitors by focusing on clinical responder analysis, drug combinations, and indication expansion.
– It can integrate private data while processing and analyzing data on a secure, federated cloud which enables integration into any pharma or health system workflow.
– The European start-up is collecting its own proprietary biomedical and clinical datasets in niche therapeutic areas with a focus on rare diseases that provide a high barrier to entry. This also enables the longer-term potential to apply the platform to develop internal drug combination programs for these rare diseases with unmet medical needs.

Stage of Development Prototype available for demonstration
Comments Regarding Stage of Development
The team is developing patient applications to collect data from rare disease patients to support its internal R&D programs.
IPR status: Secret Know-how
Profile Origin H2020 – Industrial Leadership – Innovation in SMEs (incl. SME Instrument)

Type and Role of Partner Sought
They are looking for partners from industry /academia, such as large & small pharmaceutical companies, biosimilar companies, university hospitals, partners with access to EMRs (=Electronic Medical Record) for joint ventrue, research agreement and /or licence agreement.

There’s a very high chance that they will be going directly to the patient regarding the EMRs. They will be interested to partner with the Pharma/Biotech companies and clinicians on specific diseases, starting with rare cancers like Multiple Myeloma.

The task of the partner sought is concerning
– Joint Venture Agreement: joint collaboration on R&D development
– research cooperation agreement: further development
– license agreement: the company offers the platform to licensees

Contact Person: Jana Vavrinova
Phone Number +34 981 337 146
Public Email jana.vavrinova@xunta.es

galiciabiowp
No Comments

Post a Comment

Comment
Name
Email
Website

This site uses Akismet to reduce spam. Learn how your comment data is processed.